BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Melanoma Institute Australia - ECPv6.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://melanoma.org.au
X-WR-CALDESC:Events for Melanoma Institute Australia
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Australia/Sydney
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20250405T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20251004T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20260404T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20261003T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20270403T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20271002T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20280401T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20280930T160000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Halifax
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20250309T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20251102T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20260308T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20261101T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20270314T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20271107T050000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20280312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20281105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Australia/Sydney:20260923T170000
DTEND;TZID=Australia/Sydney:20260923T170000
DTSTAMP:20260804T062200Z
CREATED:20260804T054543Z
LAST-MODIFIED:20260804T062200Z
UID:10000322-1790182800-1790182800@melanoma.org.au
SUMMARY:NHMRC Equipment Grants
DESCRIPTION:The objectives of Equipment Grants are to support Administering Institutions to: \n• be strategic in the purchase of larger items of equipment that will benefit health and medical research in Australia; \n• purchase equipment that will be used collaboratively; \n• where possible\, purchase Australian-made equipment; and \n• provide ongoing service\, upgrades\, maintenance and repair costs for equipment used on NHMRC funded Research Activities. \nThe 2026 Equipment grant opportunity is a Demand Driven (eligibility-based) process. Applications are automatically generated by NHMRC’s granting system. \n\nKey Dates:\nApplications close: 23 September 2026 \nSEE GRANT GUIDELINESSEE WEBSITE
URL:https://melanoma.org.au/event/nhmrc-equipment-grants/
CATEGORIES:Grants,Infrastructure & Equipment
ATTACH;FMTTYPE=image/jpeg:https://melanoma.org.au/wp-content/uploads/2026/07/NHMRC_Equipment_Grants-600-x-338-px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Australia/Sydney:20260923T170000
DTEND;TZID=Australia/Sydney:20260923T170000
DTSTAMP:20260804T062111Z
CREATED:20260804T054722Z
LAST-MODIFIED:20260804T062111Z
UID:10000321-1790182800-1790182800@melanoma.org.au
SUMMARY:NHMRC Independent Research Institutes Infrastructure Support Scheme
DESCRIPTION:IRIISS allocates funds for infrastructure support to independent medical research institutes managing NHMRC research funds. \nIRIISS aims to develop and maintain infrastructure to support high quality health and medical research by contributing to infrastructure costs associated with competitively awarded NHMRC research grants managed by independent medical research institutes. \nThe 2026 Independent Research Institutes Infrastructure Support Scheme grant opportunity is a Demand Driven (eligibility-based) process. \n\nKey Dates:\nApplications close: 23 September 2026 \nSEE GRANT GUIDELINESSEE WEBSITE
URL:https://melanoma.org.au/event/nhmrc-iriiss/
CATEGORIES:Grants,Infrastructure & Equipment
ATTACH;FMTTYPE=image/jpeg:https://melanoma.org.au/wp-content/uploads/2026/07/NHMRC_IRIISS-600-x-338-px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20261014T170000
DTEND;TZID=America/Halifax:20261014T170000
DTSTAMP:20260602T051105Z
CREATED:20260602T051105Z
LAST-MODIFIED:20260602T051105Z
UID:10000302-1791997200-1791997200@melanoma.org.au
SUMMARY:CDMRP Melanoma Research Program
DESCRIPTION:The Melanoma Research Program (MRP) released program announcements for the following funding opportunities: \n\n\n\n·        Focused Program Award – Rare Melanomas  \nThis award supports a multidisciplinary research program of at least two\, but not more than three\, distinct but complementary research projects addressing an overarching question relevant to rare melanomas. \n·        Idea Award \nThe Idea Award supports innovative\, exploratory\, high-risk/potentially high-reward research. Novelty and innovation are expected to be key aspects of the proposed project. By the end of the Idea Award funding period\, the anticipated outcomes of successful efforts should establish proof of principle and obtain preliminary data to secure follow-on funding. \n·        Melanoma Academy Scholar Award \nSupports the addition of independent\, early career investigators (Scholars) who are no more than seven years from their initial faculty appointment to the Melanoma Research Program (MRP) Melanoma Academy. The Melanoma Academy is a unique\, interactive virtual academy focused on bringing together established investigators and Scholars to develop a network of successful\, highly productive melanoma researchers in a collaborative research and career development environment. \n·        Survivorship Research Award \nThe award addresses the relatively new and underfunded area of melanoma-specific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors\, their families and/or their care partners in the near term. Proposed studies focusing exclusively on animal models or considering survival only without consideration of quality of life\, overall health and/or function are not responsive to this funding opportunity. \n·        Team Science Award \nSupports a broad range of hypothesis-driven\, multidisciplinary studies that have a short-term goal of advancing the state of the science in melanoma research and/or patient care. Team science is a synergistic effort that harnesses techniques\, approaches and perspectives from multiple disciplines and/or therapeutic areas to address complex\, multi-dimensional problems that will impact patient outcomes. \nKey Dates: \nSubmission Deadline (Pre-application-Pre-Proposal): 13 July 2026\nFocused Program Award – Rare Melanomas\nIdea Award\nTeam Science Award \nSubmission Deadline (Pre-application-Pre-Proposal): 22 September 2026\nMelanoma Academy Scholar Award\nSurvivorship Research Award \nApplication Submission Deadline: 14 October 2026 \n\n\n\n\n\n\n\n\n\nSEE GRANT GUIDELINESSEE WEBSITE
URL:https://melanoma.org.au/event/cdmrp-melanoma-program/
CATEGORIES:Grants,Discovery
ATTACH;FMTTYPE=image/jpeg:https://melanoma.org.au/wp-content/uploads/2026/05/CDMRP-Research-Program-600-x-338-px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Australia/Sydney:20261104T170000
DTEND;TZID=Australia/Sydney:20261104T170000
DTSTAMP:20260804T062313Z
CREATED:20260804T054341Z
LAST-MODIFIED:20260804T062313Z
UID:10000323-1793811600-1793811600@melanoma.org.au
SUMMARY:NHMRC Clinical Trials and Cohort Studies Grants
DESCRIPTION:Clinical Trials and Cohort Studies Grants support high-quality clinical trials and cohort studies that address important gaps in knowledge\, leading to relevant and implementable findings for the benefit of human health. \nThis funding scheme is open to research proposals for clinical trials and/or cohort studies of any size – that is\, they may be large or small clinical trials or cohort studies. \nThe intended outcomes of the Clinical Trials and Cohort Studies Grants scheme are improvements in health and well-being\, health care practice or policy\, as a result of: \n\nHigh-quality clinical trials that provide reliable evidence of the effects of health-related interventions on health outcomes (or appropriate surrogates).\nHigh-quality cohort studies that provide reliable evidence on the relation of important risk factors and other exposures to health-related outcomes.\nHigh quality retrospective cohort studies that provide reliable evidence on the relation of important risk factors and other exposures to health-related outcomes.\n\n\nKey Dates:\nApplications open: 9 September 2026\nMinimum data due date: 7 October 2026\nApplications close: 4 November 2026 \nGuidelines will be available when the grant opens. \nSEE GRANT GUIDELINESSEE WEBSITE
URL:https://melanoma.org.au/event/nhmrc-clinical-trials-grants/
CATEGORIES:Grants,Clinical Trial Cohorts
ATTACH;FMTTYPE=image/jpeg:https://melanoma.org.au/wp-content/uploads/2026/07/NHMRC_Clinical_Trials_Grants-600-x-338-px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20261105T170000
DTEND;TZID=America/Halifax:20261105T170000
DTSTAMP:20260804T054123Z
CREATED:20260804T054123Z
LAST-MODIFIED:20260804T054123Z
UID:10000325-1793898000-1793898000@melanoma.org.au
SUMMARY:Melanoma Research Alliance AWARDS
DESCRIPTION:The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for pre-clinical\, translational\, and early clinical research with the potential to produce unusually high impact\, near-term advancements in melanoma prevention\, detection\, diagnosis\, and treatment. \nThis cycle\, proposals will be accepted for Established Investigator Awards\, Academic-Industry Partnership Award (for Established Investigator Awards)\, Young Investigator Awards\, and Pilot Awards. \nMRA plans to support at least $7.9 million in new funding in the 2026-2027 cycle. \nSpecial Opportunities Included in RFP: \n\nAcral Melanoma Established Investigator\, Young Investigator\, and Pilot Awards focused on Advancing Translational Research for Acral Melanoma\nUveal Melanoma Established Investigator\, Young Investigator\, and Pilot Awards focused on Advancing Translational Research for Uveal Melanoma\nEstablished Investigator\, Young Investigator\, and Pilot Awards from applicants based in the United Kingdom (UK)\nEstablished Investigator\, Young Investigator\, and Pilot Awards from applicants based in Israel\n\n\nKey Dates: \n\nAugust 21\, 2026: Letters of Intent (LOI) due for Established Investigator Awards and Established Investigator Academic-Industry Partnership Award\nSeptember 14\, 2026: Eligibility Checklist and Biosketch due for Young Investigator Award applicants\nNovember 5\, 2026: Proposals due for Young Investigator and Pilot Awards\nDecember 10\, 2026: Invited Established Investigator Award full proposals due\nApril 2027: Awardees notified of funding decisions\nJune 1\, 2027: Project Start Date\n\nSEE GRANT GUIDELINESSEE WEBSITE
URL:https://melanoma.org.au/event/mra-awards/
CATEGORIES:Grants,Early to Mid Career Researcher
ATTACH;FMTTYPE=image/jpeg:https://melanoma.org.au/wp-content/uploads/2026/08/Melanoma_Research_Alliance-600-x-338-px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Australia/Sydney:20261111T170000
DTEND;TZID=Australia/Sydney:20261111T170000
DTSTAMP:20260331T013110Z
CREATED:20260331T013110Z
LAST-MODIFIED:20260331T013110Z
UID:10000276-1794416400-1794416400@melanoma.org.au
SUMMARY:NHMRC Partnership Projects
DESCRIPTION:The Partnership Project funding scheme provides funding and support to create new opportunities for researchers and policy makers to work together to define research questions\, undertake research\, interpret the findings and implement the findings into policy and practice. \n\nPartnership Projects create partnerships among decision makers\, policy makers\, managers\, clinicians and researchers and answer a specific research question to influence health and wellbeing through changes in the delivery\, organisation\, funding and access to health services. \nPartnership Projects will support collaborations\, within the Australian context\, that translate research evidence into health policy and health practice\, to improve health services and processes. \nThe objectives of the Partnership Project scheme are to: \n• Meet the need for more effective integration of research evidence into health policy and service delivery\n• Create partnerships among policy makers\, managers\, service providers and researchers\n• Provide support to answer often complex and difficult questions that policy makers\, managers and service providers face when making decisions and implementing policies that affect Australians’ health and health care\n• Be highly responsive to the priorities of government\, the community and health professionals\n• Enable applicants to apply for funding at any time during the year to allow researchers and Partner Organisations to develop timely collaborations. \n\nKey Dates for Peer Review Cycle 2:\nApplications open: 19 March 2026\nNHMRC-approved Administering Institutions waiver due: 8 July 2026\nMinimum data due: 22 July 2026\nApplications close: 5 August 2026\nPeer review meetings: 17-19 November 2026 \nKey Dates for Peer Review Cycle 3:\nApplications open: 23 July 2026\nNHMRC-approved Administering Institutions waiver due: 14 October 2026\nMinimum data due: 28 October 2026\nApplications close: 11 November 2026\nPeer review meetings: 2-4 March 2027 \nSEE GRANT GUIDELINESSEE WEBSITE
URL:https://melanoma.org.au/event/nhmrc-partnership-projects/
CATEGORIES:Grants,Industry
ATTACH;FMTTYPE=image/jpeg:https://melanoma.org.au/wp-content/uploads/2026/03/NHMRC-Partnership-600-x-338-px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270111T235900
DTEND;TZID=America/New_York:20270111T235900
DTSTAMP:20260804T053910Z
CREATED:20260804T053910Z
LAST-MODIFIED:20260804T053910Z
UID:10000326-1799711940-1799711940@melanoma.org.au
SUMMARY:Cancer Research Institute | IGNITE Award
DESCRIPTION:The CRI IGNITE Award — Inspiring Growth and Nurturing Independence Through Excellence — supports the transition of outstanding postdoctoral researchers into independent tenure-track investigators. The program offers two sequential phases of funding: \n\n\nPhase 1: Foundation Phase – Up to 2 years of postdoctoral support\nPhase 2: Independence Phase – Up to 3 years of faculty support\n\nIGNITE provides more than funding — it delivers a structured pathway to independence at a time when such opportunities are shrinking. \nPhase 1: IGNITE Foundation Phase \n\nUp to 2 years | $150\,000 per year\nProvides $90\,000 a year in salary support\, and $60\,000 to fund independent work\nProvides critical protected time\, mentorship\, and research support to help postdocs prepare for independence\n\nPhase 2: IGNITE Independence Phase \n\nUp to 3 years | $250\,000 per year\nFunding is contingent upon an adequate start-up package by the host institution\n\nSupports early faculty as they launch new labs and pursue bold\, high-impact research in cancer immunology. \nKey Dates:\nApplication deadline: 11 January\, 2027 \nSEE WEBSITE
URL:https://melanoma.org.au/event/cri-ignite-award/
CATEGORIES:Grants,Early to Mid Career Researcher
ATTACH;FMTTYPE=image/jpeg:https://melanoma.org.au/wp-content/uploads/2026/08/CRI_Ignite-600-x-338-px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270115T235900
DTEND;TZID=America/New_York:20270115T235900
DTSTAMP:20260804T053741Z
CREATED:20260804T053741Z
LAST-MODIFIED:20260804T053741Z
UID:10000327-1800057540-1800057540@melanoma.org.au
SUMMARY:Cancer Research Institute | Lloyd J. Old STAR Program
DESCRIPTION:The CRI Lloyd J. Old STAR Program — Scientists TAking Risks — provides long-term\, flexible funding to mid-career scientists\, giving them the freedom to pursue high-risk\, high-reward research at the leading edge of cancer immunotherapy. \nThe ideal candidate is a bold\, creative scientist who embraces risk in pursuit of breakthrough insights. They are distinguished by their ability to: \n\nLeverage deep expertise and visionary curiosity to frame significant\, non-obvious questions\nDraw connections across disciplines to generate and test novel hypotheses\nPursue unconventional lines of inquiry\, even at the risk of failure\, with the potential for transformative success\n\nUltimately\, CRI STARs will advance fundamental or translational discoveries that shape the development of immune-based therapies\, broadening their impact for patients worldwide. CRI STARs not only drive innovation\, they are defining the future of cancer immunology. \nThe Lloyd J. Old STAR Program provides $1.25M over a 5 year period. Institutions will be provided indirect costs of up to 10% of the total amount awarded. Indirects are provided in addition to awarded funds. \nKey Dates:\nApplication deadline: 15 January\, 2027\nInvited interview: Spring 2027 (date TBD) \nSEE WEBSITE
URL:https://melanoma.org.au/event/cri-star-program/
CATEGORIES:Grants,Early to Mid Career Researcher
ATTACH;FMTTYPE=image/jpeg:https://melanoma.org.au/wp-content/uploads/2026/08/CRI_Lloyd_Star_Program-600-x-338-px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Australia/Sydney:20270331T170000
DTEND;TZID=Australia/Sydney:20270331T170000
DTSTAMP:20260618T051009Z
CREATED:20260618T051009Z
LAST-MODIFIED:20260618T051009Z
UID:10000310-1806512400-1806512400@melanoma.org.au
SUMMARY:MRFF 2022 Frontier Health and Medical Research Grant
DESCRIPTION:This grant program will support researchers to pursue big ideas to develop new products and interventions and implement these into clinical practice\, benefiting patients\, clinicians\, and the health system. \nThis grant opportunity offers funding to support medical research and medical innovation programs of research (up to $25 million per program) that deliver a ‘moonshot’ by creating a treatment for a currently serious and incurable health condition\, through a series of linked projects. The program of research can propose to develop novel health technologies and/or re‑purpose existing health technologies in a novel way. \nThe initial application process to secure funding through this grant opportunity will be conducted in two stages: \n\nexpression of interest (EOI) – outlining a proposed program of research comprising of a series of linked projects with a 10-year time horizon\nfull application\, (invitation only – following EOI) for a project of up to 5 years under the program of research.\n\nApplicants may propose to commence research at any stage in the research pipeline from proof-of-concept\, with the intention of achieving full implementation of the proposed technology in 10 years. \nFunding for subsequent projects under the program of research that continue to progress the technology towards full implementation can be sought by submitting additional full applications to this grant opportunity (i.e. applicants do not need to recommence with an EOI). These applications may be submitted by invitation only. \n\nKey Dates:\nExpressions of Interest close: 31 March 2027\nLast grants awarded by: 30 June 2028 \nSEE GRANT GUIDELINESSEE WEBSITE
URL:https://melanoma.org.au/event/mrff-2022-frontier-grant/
CATEGORIES:Grants,Discovery
ATTACH;FMTTYPE=image/jpeg:https://melanoma.org.au/wp-content/uploads/2026/06/MRFF-2022-Frontier-Health-and-Medical-Research-Grant-600-x-338-px.jpg
END:VEVENT
END:VCALENDAR